Semaglutide and the 'lizard drug' claim: where does it come from?

What is the actual link between lizards and semaglutide?

The story starts in 1992, when endocrinologist John Eng discovered exendin-4 in the saliva of the Gila monster (Heloderma suspectum). This peptide turned out to bind human GLP-1 receptors far more tenaciously than the body's own GLP-1 hormone does, because it resists the enzyme that normally breaks GLP-1 down within minutes. That resistance gave it therapeutic potential, it stayed active long enough to lower blood sugar after a meal.

Exendin-4 became the basis for exenatide, the first GLP-1 receptor agonist approved for clinical use. Semaglutide is a different molecule entirely. It was designed by Novo Nordisk's chemists to mimic human GLP-1 directly, with modifications that extend its half-life to approximately seven days. One key modification attaches a fatty-acid chain so the molecule binds to albumin in the blood, slowing its clearance. There is no exendin-4 in semaglutide, and no Gila monster in the manufacturing process. The lizard provided conceptual proof that the GLP-1 pathway was worth targeting; the drug that emerged from that pathway later is a distinct piece of synthetic chemistry. You can read more about the broader history and mechanism on our semaglutide overview page.

The shorthand "lizard drug" or "lizard jab" circulates online as a colourful way of gesturing at this lineage. It is not clinically accurate, and the phrase occasionally deters people who worry (unnecessarily) about the medicine's origins.

Does the lizard connection change anything about how semaglutide works?

Not in practice. Semaglutide acts on the GLP-1 receptor, which is found in the pancreas, gut and brain. Activating it slows gastric emptying, reduces appetite signals in the hypothalamus, and supports post-meal insulin release. These are effects on very ordinary human physiology, the GLP-1 pathway exists in every person regardless of how the activating molecule was discovered.

What the Gila monster research did prove, practically speaking, is that you could build a compound that activates GLP-1 receptors for long enough to be clinically useful. Semaglutide takes that principle to a weekly injection or, as of June 2026, a once-daily tablet. The deeper science of the venom connection is genuinely interesting if you want to follow it further, but it has no bearing on whether semaglutide is safe or appropriate for you.

The NHS's patient information for semaglutide covers how the medicine works and its known side-effect profile; the NHS semaglutide page is a reliable starting point for anyone who wants the clinical basics in plain English.

Is Wegovy (semaglutide) the right option, and how is it accessed?

Wegovy is licensed in the UK for adults whose BMI is 30 or above, or 27 or above when at least one weight-related condition is also present, things like high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A prescriber weighs all of that alongside your full health picture; BMI is the starting point, not the verdict.

On the NHS, semaglutide for weight management is available through specialist services under NICE guidance (TA875) and waiting times can be substantial. Private access through a regulated online pharmacy removes the waiting list for people who are clinically suitable. If you are weighing up options, our Wegovy price comparison guide sets out what private treatment typically costs and what to look for in a provider. It is worth knowing that legitimately prescribed Wegovy must come through a GPhC-registered pharmacy, not through social media sellers or sites offering it without a prescription, which the MHRA has repeatedly warned carry serious safety risks. If your circumstances fall outside the standard licensed criteria, our guide to using Wegovy off label explains when that route may be considered and what it involves.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, not automated. A real clinician reviews your answers the same day. If approved, the treatment is dispatched the same day (for orders placed before 12pm, Monday to Friday) and arrives the next working day via DPD, in plain unbranded packaging, you get the tracking link, and that is the only indication of what is inside. If you are ever unsure whether a product you have seen elsewhere is genuine, our page on the Wegovy logo and packaging markings can help you identify an authentic pen. Our clinical team page introduces the prescribers who review every case.

For a broader look at how GLP-1 medicines fit into weight management, the weight-loss treatment overview covers the landscape clearly. If you think semaglutide might suit you, the next practical step is a consultation.